Compare AbbVie Inc (ABBV) vs Workday Inc (WDAY) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

Workday (WDAY) trades at $143.65, up 6.09% with strong technical momentum above key resistance at $141. The stock shows robust fundamentals with consistent earnings beats (Q1 2026 EPS of $2.66 vs. $2.51 expected) and 14.3% y/y subscription revenue growth. Recent AI product launches, including agentic AI tools with 200%+ ACV growth, position the company for continued expansion despite a recent lawsuit over AI bias in HR tools.

Outlook remains positive with 55.5% analyst buy ratings and $157.30 consensus target (9.5% upside). Key risks include the California AI bias lawsuit, competitive pressure in enterprise software, and valuation concerns at 42.99 P/E. Strong cash flow generation ($2.46B operating cash flow) supports growth investments while net cash flow turned negative due to strategic financing activities.